The AI-PROGNOSIS consortium held its 6th Plenary Meeting on 26–27 November 2025 in Nicosia, Cyprus, hosted by the Cyprus Institute of Neurology and Genetics (CING). Partners joined on-site and online to review the project’s progress and plan the work for the next months.

Reviewing progress across work packages

Throughout the two-day meeting, each work package presented its latest updates:

• WP3 shared new results from digital biomarker analyses, updates on datasets, and plans for upcoming scientific publications.

• WP5 reported on the status of the AI-PRA and AI-PMP clinical studies, including recruitment, logistics, ethical approvals, and preparation of key study deliverables.

• WP4 presented progress on the system architecture and demonstrated the current features of the mAI-Health, mAI-Care, and mAI-Insights applications.

• WP1 provided updates on reporting, data protection, access policies, and project governance.

• WP2 discussed data harmonisation work, pending dataset access, and next steps for the sensor data repository.

• WP6 gave an overview of dissemination and stakeholder engagement activities, networking with related projects, patient involvement, and initial steps toward exploitation and regulatory planning.

  
  

The consortium also held a General Assembly session to discuss effort and budget reallocation and the need for a potential 6-month project extension due to delays in study initiation.

Focused sessions and expert feedback

The meeting included special sessions dedicated to:

• reviewing and finalising the AI-PRA study protocol,

• discussing outstanding study logistics and responsibilities across clinical sites,

An External Expert Advisory Board (EEAB) session was also held, where board members reviewed project progress and provided valuable scientific and strategic feedback.

Moving forward

The plenary meeting concluded with a summary of agreed actions and priorities for the coming months. Partners will now focus on:

• preparing for the initiation and smooth running of the clinical studies,

• advancing system development and data infrastructure,

• continuing scientific work on digital biomarkers and predictive models,

• and delivering the next milestones and deliverables planned for early 2026.